{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:06:06Z","timestamp":1787317566954,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.xphs.2022.05.017","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T19:06:17Z","timestamp":1653159977000},"page":"3424-3434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80\u2013Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-6997","authenticated-orcid":false,"given":"Kendall B.","family":"Preston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-657X","authenticated-orcid":false,"given":"Teri Ann S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-9803","authenticated-orcid":false,"given":"Albert","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Thomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Misamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Yalley-Ogunro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehtap","family":"Cabus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreola","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-203X","authenticated-orcid":false,"given":"Axel T.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4292-4047","authenticated-orcid":false,"given":"Theodore W.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.05.017_bib0001","unstructured":"U.S. Food and Drug Administration. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. Accessed January 16, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health"},{"key":"10.1016\/j.xphs.2022.05.017_bib0002","unstructured":"European Medicines Agency. Zabdeno (Ad26.ZEBOV-GP, recombinant). Published 2020. Accessed September 13, 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zabdeno"},{"key":"10.1016\/j.xphs.2022.05.017_bib0003","unstructured":"European Medicines Agency. Mvabea (MVA-BN-Filo, recombinant). Published 2020. Accessed September 13, 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvabea"},{"issue":"6","key":"10.1016\/j.xphs.2022.05.017_bib0004","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/infdis\/jiv532","article-title":"Stability of a vesicular stomatitis virus-vectored ebola vaccine","volume":"213","author":"Arnemo","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.xphs.2022.05.017_bib0005","first-page":"1","article-title":"Forty-two years of responding to Ebola virus outbreaks in Sub-Saharan Africa: a review","volume":"5","author":"Rugarabamu","year":"2020","journal-title":"BMJ Glob Heal"},{"issue":"2","key":"10.1016\/j.xphs.2022.05.017_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/153834402320882593","article-title":"Lyophilization and the thermostability of vaccines","volume":"1","author":"Rexroad","year":"2002","journal-title":"Cell Preserv Technol"},{"issue":"5","key":"10.1016\/j.xphs.2022.05.017_bib0007","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.09.20","article-title":"Opportunities and challenges of developing thermostable vaccines","volume":"8","author":"Chen","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.xphs.2022.05.017_bib0008","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2021.01.016","article-title":"Stability of lyophilized and spray dried vaccine formulations","volume":"171","author":"Preston","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"39","key":"10.1016\/j.xphs.2022.05.017_bib0009","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1016\/j.vaccine.2021.08.003","article-title":"Single-vial filovirus glycoprotein vaccines: biophysical characteristics and immunogenicity after co-lyophilization with adjuvant","volume":"39","author":"Preston","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.xphs.2022.05.017_bib0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.vaccine.2004.07.021","article-title":"Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition","volume":"23","author":"Blom","year":"2004","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.xphs.2022.05.017_bib0011","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.xphs.2017.02.024","article-title":"Feasibility of freeze-drying oil-in-water emulsion adjuvants and subunit proteins to enable single-vial vaccine drug products","volume":"106","author":"Iyer","year":"2017","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2022.05.017_bib0012","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.02.047","article-title":"Freeze-drying of emulsified systems: a review","volume":"503","author":"Morais","year":"2016","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2022.05.017_bib0013","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1002\/jps.21786","article-title":"Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate","volume":"98","author":"Lee","year":"2009","journal-title":"J Pharm Sci"},{"issue":"22","key":"10.1016\/j.xphs.2022.05.017_bib0014","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2017.01.068","article-title":"Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice","volume":"36","author":"Lehrer","year":"2018","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.xphs.2022.05.017_bib0015","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1016\/j.vaccine.2019.06.035","article-title":"Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge","volume":"37","author":"Lehrer","year":"2019","journal-title":"Vaccine"},{"issue":"2019","key":"10.1016\/j.xphs.2022.05.017_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejpb.2019.01.019","article-title":"Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide","volume":"136","author":"Chisholm","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"10.1016\/j.xphs.2022.05.017_bib0017","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.xphs.2020.09.011","article-title":"Preservation of quaternary structure in thermostable, lyophilized filovirus glycoprotein vaccines: a search for stability-indicating assays","volume":"109","author":"Preston","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.05.017_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant protein filovirus vaccines protect cynomolgus macaques from ebola, sudan, and marburg viruses","volume":"12","author":"Lehrer","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2022.05.017_bib0019","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijbiomac.2015.10.048","article-title":"Evaluation of antioxidants in protein formulation against oxidative stress using various biophysical methods","volume":"82","author":"Hada","year":"2016","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.xphs.2022.05.017_bib0020","series-title":"Vaccine Adjuvants: Methods and Protocols","article-title":"Vaccine Adjuvants: Methods and Protocols","author":"Fox","year":"2017"},{"issue":"1","key":"10.1016\/j.xphs.2022.05.017_bib0021","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr Purif"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2022.05.017_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2007.06.042","article-title":"Dual effects of Tween 80 on protein stability","volume":"347","author":"Wang","year":"2008","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2022.05.017_bib0023","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1007\/s11095-011-0385-x","article-title":"The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics","volume":"28","author":"Kishore","year":"2011","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2022.05.017_bib0024","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/jps.21190","article-title":"Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways","volume":"97","author":"Kerwin","year":"2008","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2022.05.017_bib0025","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/jps.10216","article-title":"Peroxide formation in polysorbate 80 and protein stability","volume":"91","author":"Ha","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.05.017_bib0026","series-title":"Rational Design of Stable Protein Formulations. Vol 13","first-page":"109","article-title":"Rational design of stable lyophilized protein formulations: theory and practice","author":"Carpenter","year":"2002"},{"key":"10.1016\/j.xphs.2022.05.017_bib0027","series-title":"Rational Design of Liquid Formulations of Proteins. Vol 112","author":"Manning","year":"2018"},{"issue":"17","key":"10.1016\/j.xphs.2022.05.017_bib0028","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.2217\/nnm.14.193","article-title":"The impact of size on particulate vaccine adjuvants","volume":"9","author":"Shah","year":"2014","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.xphs.2022.05.017_bib0029","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1080\/21645515.2015.1046660","article-title":"Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants","volume":"11","author":"Iyer","year":"2015","journal-title":"Hum Vaccin"},{"issue":"12","key":"10.1016\/j.xphs.2022.05.017_bib0030","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jps.2600671211","article-title":"Autoxidation of polysorbates","volume":"67","author":"Donbrow","year":"1978","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.05.017_bib0031","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jps.22290","article-title":"Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis","volume":"100","author":"Kishore","year":"2011","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2022.05.017_bib0032","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-018-2430-5","article-title":"Considerations for the use of polysorbates in biopharmaceuticals","volume":"35","author":"Jones","year":"2018","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.05.017_bib0033","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/138920109788488932","article-title":"Mechanisms of protein aggregation","volume":"10","author":"Philo","year":"2009","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.xphs.2022.05.017_bib0034","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2015.02.005","article-title":"CMC determination of nonionic surfactants in protein formulations using ultrasonic resonance technology","volume":"92","author":"Horiuchi","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2022.05.017_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-012-9878-0","article-title":"Effect of Polysorbate 80 concentration on thermal and photostability of a monoclonal antibody","volume":"14","author":"Agarkhed","year":"2013","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.xphs.2022.05.017_bib0036","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jps.20726","article-title":"Evaluation of hydroperoxides in common pharmaceutical excipients","volume":"96","author":"Wasylaschuk","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.05.017_bib0037","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/VDT.S41998","article-title":"Forced degradation studies: an essential tool for the formulation development of vaccines","author":"Ausar","year":"2013","journal-title":"Vaccine Dev Ther"},{"issue":"5","key":"10.1016\/j.xphs.2022.05.017_bib0038","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/bit.260480511","article-title":"Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization","volume":"48","author":"Li","year":"1995","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.xphs.2022.05.017_bib0039","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2013.12.025","article-title":"Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization","volume":"177","author":"Orr","year":"2014","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.xphs.2022.05.017_bib0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"10.1016\/j.xphs.2022.05.017_bib0041","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.addr.2006.09.017","article-title":"Freeze-drying of nanoparticles: formulation, process and storage considerations","volume":"58","author":"Abdelwahed","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2022.05.017_bib0042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijpharm.2007.08.011","article-title":"The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization","volume":"349","author":"Li","year":"2008","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2022.05.017_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00423-3","article-title":"Lyophilization and development of solid protein pharmaceuticals","volume":"203","author":"Wang","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2022.05.017_bib0044","first-page":"295","article-title":"Development of a lyophilized formulation of interleukin-2","volume":"74","author":"Hora","year":"1992","journal-title":"Dev Biol Stand"},{"issue":"17","key":"10.1016\/j.xphs.2022.05.017_bib0045","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1021\/ac900855f","article-title":"Cold chemical oxidation of proteins","volume":"81","author":"Hambly","year":"2009","journal-title":"Anal Chem"},{"issue":"6","key":"10.1016\/j.xphs.2022.05.017_bib0046","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.xphs.2016.03.034","article-title":"Hydrogen peroxide induced protein oxidation during storage and lyophilization process","volume":"105","author":"Cheng","year":"2016","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2022.05.017_bib0047","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10837450701481157","article-title":"Protein stability during freezing: separation of stresses and mechanisms of protein stabilization","volume":"12","author":"Bhatnagar","year":"2007","journal-title":"Pharm Dev Technol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922002155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922002155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:40:10Z","timestamp":1758361210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922002155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0022354922002155"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.05.017","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80\u2013Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}